Literature DB >> 1428784

Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS.

A Antinori1, A Ammassari, G Maiuro, G Camilli, F Damiano, G Federico, E Pizzigallo, E Tamburrini.   

Abstract

We retrospectively examined 39 patients with AIDS and central nervous system toxoplasmosis in order to determine the efficacy and safety of two combinations: pyrimethamine-sulfadiazine and pyrimethamine-clindamycin. The results showed a response rate of 79% for the sulfadiazine association and a high failure rate in the clindamycin group. Side effects with sulfadiazine were slightly more frequent, but with desensitization protocols discontinuation was kept down. The combination of pyrimethamine and sulfadiazine, associated, when necessary, with desensitization schedules, was confirmed to be first choice therapy for cerebral toxoplasmosis in AIDS patients. The role of alternative regimens needs further evaluation.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1428784     DOI： 10.1007/bf02230867

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  8 in total

1.  Clindamycin for toxoplasma encephalitis in AIDS.

Authors:  J S Remington; J L Vildé
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

3.  An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis.

Authors:  C Leport; S Bastuji-Garin; C Perronne; D Salmon; C Marche; F Briçaire; J L Vilde
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

4.  Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis.

Authors:  M Tenant-Flowers; M J Boyle; D Carey; D J Marriott; J L Harkness; R Penny; D A Cooper
Journal:  AIDS       Date:  1991-03       Impact factor: 4.177

5.  Treatment of toxoplasmic encephalitis with intravenous clindamycin.

Authors:  B R Dannemann; D M Israelski; J S Remington
Journal:  Arch Intern Med       Date:  1988-11

6.  Treatment of acute toxoplasmosis with intravenous clindamycin. The California Collaborative Treatment Group.

Authors:  B R Dannemann; J A McCutchan; D M Israelski; D Antoniskis; C Leport; B J Luft; J Chiu; J L Vildé; J N Nussbaum; M Orellana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

7.  Role of clindamycin in the treatment of central nervous system toxoplasmosis.

Authors:  K V Rolston; J Hoy
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

8.  Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  J Fernandez-Martin; C Leport; P Morlat; M C Meyohas; J P Chauvin; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191
  8 in total
  3 in total

1.  Sulfadiazine Plus Pyrimethamine Therapy Reversed Multiple Behavioral and Neurocognitive Changes in Long-Term Chronic Toxoplasmosis by Reducing Brain Cyst Load and Inflammation-Related Alterations.

Authors:  Barrios Leda Castaño; Andrea Alice Silva; Lina L Hernandez-Velasco; Ana Paula Da Silva Pinheiro; Daniel Gibaldi; José Roberto Mineo; Neide Maria Silva; Joseli Lannes-Vieira
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

2.  Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Authors:  F M Notarangelo; E H Wilson; K J Horning; M A R Thomas; T H Harris; Q Fang; C A Hunter; R Schwarcz
Journal:  Schizophr Res       Date:  2013-12-15       Impact factor: 4.939

Review 3.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.